Protocol to Distinguish Tumor Recurrence From Treatment-Related Necrosis in Patients With High Grade Gliomas

Completed

Conditions studied: Recurrent High Grade Gliomas

In brief

Brain imaging tests are routinely used to detect the presence of a brain tumor or to evaluate the response to treatment. Sometimes the images obtained are not specific and the only way to establish a diagnosis is by obtaining a tissue sample. The hypotheses of the study is to determine if multimodal MR technique will provide tissue signatures that differentiate between tumor progression and treatment related necrosis in high grade glioma patients.

Key facts

Study ID

NCT00942760

Run by

Dartmouth-Hitchcock Medical Center

People needed

12

Starts

2009-04-01

Expected to finish

2011-04-01

Last updated by the study team

2013-05-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically proven high grae glioma with central pathology review at DHMC
• Age 18 equal to or greater than 18 years
• Karnofsky performance greater or equal to 60%
• Patients must have received radiation therapy and chemotherapy but should not have received any anti-angiogenesis therapy.

You may not qualify if…

• Any patient who requires urgent surgical resection of MRI abnormality would not be eligible
• Pregnant women are not eligible

Where it is running

• Dartmouth-Hitchcock Medical Center — Lebanon, New Hampshire, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.